Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1057466 | 0.92 | SMO (0.42) | SMOMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1062880 | 0.88 | SMO (0.46) | SMOMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL4295234 | 0.88 | SMO (0.46) | SMOMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1062882 | 0.88 | SMO (0.46) | SMOMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL10314454 | 0.87 | SMO (0.45) | SMOMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL10314230 | 0.87 | SMO (0.45) | SMOMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1063316 | 0.87 | SMO (0.45) | SMOMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1063318 | 0.87 | SMO (0.45) | SMOMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL10314460 | 0.87 | SMO (0.45) | SMOMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL1062284 | 0.87 | SMO (0.40) | SMOMEN1ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399449-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | SMO 1/4885MEN1 1922/4885ALDH1A1 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.